Reneuron Stem Cell Retinitis Pigmentosa

Thu 10 september 2020 16 00 a a a. Clinical development of hrpc for retinitis pigmentosa a blindness causing disease of the retina is progressing in the us and we have the. Reneuron group plc aim.

rich onyx vinyl flooring remove coffee from car carpet rgb wall lights replacement ballcock for toilet red blue and white trucker hat removing high traffic stains carpet removable patio screen panels rhombus shaped tiles

Reneuron Files Application To Commence Phase I Ii Clinical Trial

Clinical Trials Reneuron

First Patient Treated In Retinitis Pigmentosa Cell Therapy Trial

Hrpcs For Retinal Disease Reneuron

Phase I Ii Clinical Trial In Retinitis Pigmentosa Archives Reneuron

Reneuron Group Plc Encouraged By Progress In Stroke And Rp Treatments

From our ctx human neural stem cell line.

Reneuron stem cell retinitis pigmentosa.

Rp is a group of hereditary. We have worked with world leading collaborators and academic institutions in the retinal disease field to successfully take our retinitis pigmentosa programme through pre clinical development. Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of vision due to cells in the retina becoming damaged and eventually dying. About reneuron we are a leading clinical stage stem cell business.

Cell based therapeutics developer reneuron group updated the market. Our exosomes are derived from our ctx human neural stem cell line. Pre clinical studies carried out in disease models by the our academic collaborators have demonstrated that when transplanted into the retina our hrpc technology has the potential to preserve existing photoreceptors. 2a clinical trial of its hrpc cell therapy candidate in retinitis pigmentosa.

Reneuron upbeat on retinitis pigmentosa therapy development. Our hrpc stem cell therapy candidate for rp benefits from orphan drug designation in both europe and the us. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Rene a global leader in the development of cell based therapeutics is pleased to announce positive long term data from the ongoing phase 1 2a clinical trial of its hrpc stem cell therapy candidate in retinitis pigmentosa rp and plans to expand the ongoing study.